Search clinical trials for: EGFr

Total 1599 results

Tianjin Medical University Cancer Institute and...

Recruiting

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Non Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IV

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)

Carcinoma, Non-small-Cell Lung

United States, Korea, Republic of, Italy, Israel, Malaysia, United Kingdom, China, Brazil, Spain, Germany, Japan, France
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Hasselt University

Recruiting

Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD

Acute Exacerbation of COPD | Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Belgium
Konkuk University Medical Center
Yuhan Corporation

Recruiting

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Non Small Cell Lung Cancer

Korea, Republic of
Allist Pharmaceuticals, Inc.

Not yet recruiting

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

NSCLC
Peking Union Medical College

Recruiting

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC | Brain Metastases | Furmonertinib | EGFR-mutation

China
Myung-Ju Ahn

Recruiting

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

NSCLC

Korea, Republic of
Peking Union Medical College

Recruiting

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Non-small Cell Lung Cancer | EGFR T790M | Osimertinib | ddPCR

China
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Instituto Nacional de Cancerologia de Mexico

Recruiting

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (METLUNG)

Non Small Cell Lung Cancer

Mexico
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Advanced or Metastatic NSCLC

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Tang-Du Hospital

Recruiting

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Non-small Cell Lung Cancer

China
University of Milan

Recruiting

Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD

COPD | Dyspnea | Argininemia

Italy
Karen Reckamp, MD, MS
Enviro Therapeutics, Inc.

Recruiting

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumor

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer | EGFR Gene Mutation

China
J Ints Bio

Recruiting

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

EGFR Mutant Advanced Non-small Cell Lung Cancer

Korea, Republic of, United States, Thailand
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Hunan Province Tumor Hospital

Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Non-Small Cell Lung Cancer

China
Samsung Medical Center

Not yet recruiting

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | EGFR T790M

Korea, Republic of
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands, Italy
Shanghai Henlius Biotech

Not yet recruiting

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor

China
Fred Hutchinson Cancer Center
Nektar Therapeutics

Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditions

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

EGFR/ B7H3-positive Advanced Lung Cancer | EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer

China
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Sun Yat-sen University
GeneCast Biotechnology Co., Ltd.; Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA (FOCUS-C)

Non-small Cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

NSCLC | Other Solid Tumors

Australia
Jin Hyoung Kang

Recruiting

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Lung Neoplasms

Korea, Republic of
ORIC Pharmaceuticals

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors

Korea, Republic of, United States, Australia, Taiwan, Poland, Canada, Hong Kong, United Kingdom
Fudan University

Not yet recruiting

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Pancreatic Neuroendocrine Neoplasm

China
N.N. Blokhin National Medical Research Center of...

Recruiting

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (TRUST)

Non Small Cell Lung Cancer | EGFR Gene Mutation | T790M

Russian Federation
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
Amsterdam UMC, location VUmc

Recruiting

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)

Non-Small Cell Lung Cancer

Netherlands
Bursa Yüksek İhtisas Education and Research Hospital

Recruiting

Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia

Pneumonia, Viral | COVID-19 Pneumonia | EGFR Amplification

Turkey
Eastern Cooperative Oncology Group
Janssen, LP

Recruiting

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

T-cell Acute Lymphoblastic Leukemia

United States
Hunan Province Tumor Hospital

Recruiting

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer (Awesome)

Non Small Cell Lung Cancer

China
Goethe University

Recruiting

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IV | NSCLC Stage IIIB

Germany
Yonsei University

Not yet recruiting

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations (LU21-16)

NSCLC

Korea, Republic of
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Qingdao Central Hospital

Recruiting

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

China
Tianjin Medical University Cancer Institute and...

Recruiting

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase Inhibitor

China
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
British Columbia Cancer Agency

Recruiting

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Non Small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis

Canada

Search clinical trials for: EGFr

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations